DE
Therapeutic Areas
Ocean Biomedical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCEA-101 (CSPG4 mAb) | Non-Small Cell Lung Cancer, Melanoma | Preclinical |
| Fibrosis Program | NASH / Liver Fibrosis | Discovery/Preclinical |
| Malaria Program | Plasmodium vivax Malaria | Preclinical |
| B7-H3 Program | Solid Tumors | Discovery |
Leadership Team at Ocean Biomedical
DC
Dr. Chirinjeev Kathuria, MD
Co-Founder and Executive Chairman
SA
Suren Ajjarapu, CPA
Chief Financial Officer